close

Idenix Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of drugs for the treatment of human viral and other infectious diseases in the United States and Europe. The company's primary product includes Tyzeka/Sebivo for the treatment of hepatitis B virus. It also develops IDX899, a non-nucleoside reverse transcriptase inhibitor (NNRTI), for the treatment of human immunodeficiency virus (HIV)/ acquired immune deficiency syndrome (AIDS). In addition, Idenix Pharmaceuticals, Inc. focuses on the development of drugs for the treatment of hepatitis C virus. It has a license agreement with GlaxoSmithKline to develop, manufacture, and commercialize its NNRTI compounds, including IDX899 for the treatment of HIV/AIDS. The company was founded in 1998 and is headquartered in Cambridge, Massachusetts. Idenix Pharmaceuticals, Inc. is a subsidiary of Novartis Pharma AG.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	11.36
Volume	848317
Volume Avg	(mio) 2.35
52 Week High	15.25
52 Week Low	2.67
PE	N/A
PE (group average)	39
EPS Year	-0.57
EPS change Q/Q	-50%
EPS change Q/Q Yr ago	-54.17%
EPS change Q/Q next Q est	-35.29%
EPS change Y/Y	-20.27%
REV change Q/Q	66.67%
REV change Q/Q Yr ago	48.15%
EPS next Q est	-0.17
EPS next Y est	-0.57
Divident Annual	0.00
Dividend Yield	0%